GUARD THERAPEUTICS
Guard Therapeutics develops innovative drugs for the treatment of oxidative stress and acute kidney disease.
GUARD THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science
Founded:
2008-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.guardtherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+46 46-286 50 30
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Apple Mobile Web Clips Icon Nginx Visa Shutterstock Craft
Similar Organizations
Halo Therapeutics
Halo Therapeutics develops antivirals to prevent users from sickness.
Official Site Inspections
http://www.guardtherapeutics.com Semrush global rank: 5.99 M Semrush visits lastest month: 1.37 K
- Host name: 188-126-67-242-static.glesys.net
- IP address: 188.126.67.242
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "Guard Therapeutics"
Guard Therapeutics
Nov 13, 2024 Guard Therapeutics är ett svenskt bioteknikbolag i klinisk fas som identifierar och utvecklar nya terapier mot sjukdomar med ett stort medicinskt behov, med fokus på olika former av njursjukdom.See details»
About Guard Therapeutics
The fight against kidney disease. Guard Therapeutics is a Swedish biotechnology company developing innovative drugs in areas with significant medical needs, with a particular focus on kidney disease.See details»
Guard Therapeutics - Crunchbase Company Profile & Funding
Organization. Guard Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone Number +46 46-286 50 30; Lists Featuring This Company. Edit Lists Featuring This Company Section. Scandinavia Companies With Fewer Than 100 Employees (Top 10K)See details»
Guard Therapeutics - LinkedIn
Guard Therapeutics is developing innovative therapies focusing on kidney diseases. The company's lead clinical asset, RMC-035, is in phase 2b development for the prevention and treatment of kidney ...See details»
GUARD Company Description - Stock Analysis
Nov 22, 2024 Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden.See details»
Guard Therapeutics - Company Profile - Tracxn
Nov 5, 2024 Guard Therapeutics - Developer of drugs for acute kidney disease. Raised a total funding of $11.1M over 1 round from 4 investors. Guard Therapeutics has 110 competitors.See details»
Guard Therapeutics - Overview, News & Competitors - ZoomInfo
View Guard Therapeutics (www.guardtherapeutics.com) location in Stockholm, Sweden , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Guard Therapeutics International AB (publ) - Financial Times
Nov 1, 2024 Guard Therapeutics International AB (publ) (5LH0:MUN) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Management - Guard Therapeutics
Karin Botha. CFO. CFO since September 2020. Born 1973. Karin Botha holds a Degree of Master of Science in Business Administration and Economics and has more than 20 years of working experience from leading roles within finance in …See details»
Guard Therapeutics: Contact Details and Business Profile
Guardtherapeutics.com; View Similar People. Related Companies SARomics Biostructures AB. 32 $1m BONESUPPORT AB. 147 $7.3m Bactiguard AB. 100 $58m Heliospectra AB. 24 $25m Biolin Scientific AB. 75 $26m Pelago Bioscience AB. 54 $2m ...See details»
Guard Therapeutics receives its first regulatory approval for the …
Apr 15, 2024 Tobias Agervald, CEO Telephone: +46 8 670 65 51 E-mail: [email protected] About Guard Therapeutics Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments.See details»
Guard Therapeutics - Craft
Guard Therapeutics International (formerly A1M Pharma) is a company developing drugs for the treatment of serious kidney diseases. Its biological drug candidate, ROSgard, mimics the body’s own powerful defense system against oxidative stress.See details»
The Board - Guard Therapeutics
Johannes Hulthe. Non-Executive Member of the board. Board member since May 2019. Born 1970. Johannes Hulthe is a PhD and MSc in Economics. Previous experience: Johannes Hulthe has more than 17 years of experience from the pharmaceutical industry. Lecturer in cardiovascular prevention at Sahlgrenska University Hospital, Gothenburg.See details»
Guard Therapeutics - PitchBook
Guard Therapeutics General Information Description. Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.See details»
Guard Therapeutics presenterade utvecklingsstrategi och nya
Jan 31, 2024 E-post: [email protected]. Om Guard Therapeutics. Guard Therapeutics är ett svenskt bioteknikbolag som identifierar och utvecklar nya terapier mot sjukdomar med ett stort medicinskt behov av effektivare behandlingar. Bolagets kliniska läkemedelskandidat RMC-035 utvecklas som en njurskyddande behandling i samband öppen …See details»
Guard Therapeutics International AB (publ) (GUARD.ST) - Yahoo …
Find the latest Guard Therapeutics International AB (publ) (GUARD.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Guard Therapeutics provides in-depth information on phase 2 …
Tobias Agervald, CEO Telephone: +46 8 670 65 51 E-mail: [email protected] About Guard Therapeutics Guard Therapeutics is a pharmaceutical company that identifies and develops new therapies for diseases with a great medical need for more effective treatments.See details»
Guard Therapeutics – Industrifonden
Guard Therapeutics is a Swedish biotech company on a mission to provide breakthrough treatment for patients with acute kidney injury. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery.See details»
Press releases - Guard Therapeutics
Aug 27, 2024 The board of directors of Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”), in accordance with the announcement of a non-guaranteed rights issue (repair issue) which was communicated through the Company’s press release on 17 June 2024, has today resolved to carry out a new issue of shares with preferential rights for …See details»